Outcome of Liver Transplant Patients With Intraoperative-Detected Portal Vein Thrombosis: A Retrospective Cohort Study in Shiraz, Iran

Objective: to evaluate current practice and outcomes of pregnancy in women previously diagnosed with Budd-Chiari syndrome and/or portal vein thrombosis, with and without concomitant portal hypertension. Design and setting: multicentre retrospective cohort study between 2008-2021 Population: Women who conceived in the predefined period after the diagnosis of Budd-Chiari syndrome and/or portal vein thrombosis Methods and main outcome measures: We collected data on diagnosis and clinical features. The primary outcomes were maternal mortality and live birth rate. Secondary outcomes included maternal, neonatal and obstetric complications. Results: Forty-five women (12 Budd-Chiari syndrome, 33 portal vein thrombosis; 76 pregnancies) were included. Underlying prothrombotic disorders were present in 23 of 45 women (51%). Thirty-eight women (84%) received low-molecular-weight heparin during pregnancy. Of 45 first pregnancies, 11 (24%) ended in pregnancy loss and 34 (76%) resulted in live birth of which 27 at term age (79% of live births and 60% of pregnancies). No maternal deaths were observed, one woman developed pulmonary embolism during pregnancy and two women (4%) had variceal bleeding requiring intervention. Conclusions: The high number of term live births (79%) and lower than expected risk of pregnancy-related maternal and neonatal morbidity in our cohort suggest that Budd-Chiari syndrome and/or portal vein thrombosis should not be considered as an absolute contra-indication for pregnancy. Individualized, nuanced counselling and a multidisciplinary pregnancy surveillance approach are essential in this patient population.

Download Full-text

Clinical Impact of Portal Vein Thrombosis Prior to Liver Transplantation: A Retrospective Cohort Study

Annals of Hepatology ◽

10.5604/16652681.1231584 ◽

2017 ◽

Vol 16 (2) ◽

pp. 236-246 ◽

Cited By ~ 4

Author(s):

Constantine J. Karvellas ◽

Filipe S. Cardoso ◽

Marco Senzolo ◽

Malcolm Wells ◽

Mansour G. Alghanem ◽

...

Keyword(s):

Liver Transplantation ◽

Cohort Study ◽

Portal Vein ◽

Portal Vein Thrombosis ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Clinical Impact ◽

Vein Thrombosis

Download Full-text

Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases

EClinicalMedicine ◽

10.1016/j.eclinm.2021.101061 ◽

2021 ◽

Vol 39 ◽

pp. 101061

Author(s):

Maxime Taquet ◽

Masud Husain ◽

John R Geddes ◽

Sierra Luciano ◽

Paul J Harrison

Keyword(s):

Cohort Study ◽

Portal Vein ◽

Venous Thrombosis ◽

Portal Vein Thrombosis ◽

Retrospective Cohort Study ◽

Cerebral Venous Thrombosis ◽

Retrospective Cohort ◽

Vein Thrombosis

Download Full-text

Pregnancy outcomes in women with Budd–Chiari syndrome or portal vein thrombosis: a multicentre retrospective cohort study

BJOG An International Journal of Obstetrics & Gynaecology ◽

10.1111/1471-0528.17002 ◽

2021 ◽

Author(s):

YY Chung ◽

MA Heneghan

Keyword(s):

Cohort Study ◽

Portal Vein ◽

Portal Vein Thrombosis ◽

Retrospective Cohort Study ◽

Pregnancy Outcomes ◽

Retrospective Cohort ◽

Budd Chiari Syndrome ◽

Vein Thrombosis ◽

Chiari Syndrome

Download Full-text

Mini commentary on BJOG-21-0823: Pregnancy outcomes in women with Budd-Chiari syndrome or portal vein thrombosis - A multicentre retrospective cohort study.

10.22541/au.163388675.55098073/v1 ◽

2021 ◽

Author(s):

Yooyun Chung ◽

Michael Heneghan

Keyword(s):

Cohort Study ◽

Portal Vein ◽

Portal Vein Thrombosis ◽

Retrospective Cohort Study ◽

Pregnancy Outcomes ◽

Retrospective Cohort ◽

Budd Chiari Syndrome ◽

Vein Thrombosis ◽

Chiari Syndrome

Download Full-text

Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases

10.1101/2021.04.27.21256153 ◽

2021 ◽

Author(s):

Maxime Taquet ◽

Masud Husain ◽

John R Geddes ◽

Sierra Luciano ◽

Paul Harrison

Keyword(s):

Cohort Study ◽

Portal Vein ◽

Venous Thrombosis ◽

Portal Vein Thrombosis ◽

Retrospective Cohort Study ◽

Cerebral Venous Thrombosis ◽

Retrospective Cohort ◽

Matched Cohort ◽

Vein Thrombosis ◽

Icd 10

Objectives: To estimate the absolute risk of cerebral venous thrombosis (CVT) and portal vein thrombosis (PVT) in the two weeks following a diagnosis of COVID-19, and to assess the relative risks (RR) compared to influenza or the administration of an mRNA vaccine against COVID-19. Design: Retrospective cohort study based on an electronic health records network Setting: Linked records between primary and secondary care centres within 59 healthcare organisations, primarily in the USA Participants: All patients with a confirmed diagnosis of COVID-19 between January 20, 2020 and March 25, 2021 were included (N=537,913, mean [SD] age: 46.2 [21.4] years; 54.9% females). Cohorts (matched for age, sex, and race) of participants diagnosed with influenza (N=392,424) or receiving the BNT162b2 or mRNA-1273 vaccine (N=366,869) were used for comparison. Main outcome measures: Diagnosis of CVT (ICD-10 code I67.6) or PVT (ICD-10 code I81) within 2 weeks after a diagnosis of COVID-19. Results: The incidence of CVT after COVID-19 diagnosis was 42.8 per million people (95% CI 28.5-64.2) including 35.3 per million (95% CI 22.6-55.2) first diagnoses. This was significantly higher than the CVT incidence in a matched cohort of patients with influenza (RR=3.83, 95% CI 1.56-9.41, P<0.001) and people who received an mRNA vaccine (RR=6.67, 95% CI 1.98-22.43, P<0.001). The incidence of PVT after COVID-19 diagnosis was 392.3 per million people (95% CI 342.8-448.9) including 175.0 per million (95% CI 143.0-214.1) first diagnoses. This was significantly higher than the PVT incidence in a matched cohort of patients with influenza (RR=1.39, 95% CI 1.06-1.83, P=0.02) and people who received an mRNA vaccine (RR=7.40, 95% CI 4.87-11.24, P<0.001). Mortality after CVT and PVT was 17.4% and 19.9% respectively. Conclusions: The incidence of CVT and PVT is significantly increased after COVID-19. The data highlight the risk of serious thrombotic events in COVID-19 and can help contextualize the risks and benefits of vaccination in this regard.

Download Full-text